Next Article in Journal
Acknowledgement to Reviewers of Cancers in 2015
Next Article in Special Issue
Conditional Melanoma Cancer Survival in the United States
Previous Article in Journal
Cancer-Related Constituents of Strawberry Jam as Compared with Fresh Fruit
Previous Article in Special Issue
Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy
Article Menu

Export Article

Open AccessReview
Cancers 2016, 8(1), 17;

Updates in Therapy for Advanced Melanoma

Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
Division of Medical Oncology, Department of Internal Medicine, Duke University Medical Center, Durham, NC 27710, USA
Author to whom correspondence should be addressed.
Academic Editor: Chyi-Chia Richard Lee
Received: 11 September 2015 / Revised: 4 January 2016 / Accepted: 7 January 2016 / Published: 15 January 2016
(This article belongs to the Special Issue Current Topics in Cutaneous Melanoma)
Full-Text   |   PDF [607 KB, uploaded 15 January 2016]   |  


Cutaneous melanoma is one of the most aggressive forms of skin cancer, and is correlated with a large proportion of skin cancer-related deaths. Therapy for cutaneous melanoma has advanced greatly through careful identification of therapeutic targets and the development of novel immunotherapeutic approaches. The identification of BRAF as well as other driver mutations, have allowed for a specialized approach to treatment. In addition, immune checkpoint inhibition has dramatically changed the treatment landscape over the past 5–10 years. The successful targeting of CTLA-4, as well as PD-1/PD-L1, has been translated into meaningful clinical benefit for patients, with multiple other potential agents in development. Systemic therapy for cutaneous melanoma is becoming more nuanced and often takes a multifaceted strategy. This review aims to discuss the benefits and limitations of current therapies in systemic melanoma treatment as well as areas of future development. View Full-Text
Keywords: melanoma; immunotherapy; targeted therapy; CTLA-4; PD-1; BRAF; MEK melanoma; immunotherapy; targeted therapy; CTLA-4; PD-1; BRAF; MEK

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Singh, B.P.; Salama, A.K.S. Updates in Therapy for Advanced Melanoma. Cancers 2016, 8, 17.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top